Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Melanoma other imaging findings

Introduction

Overview

Overview

Dynamic contrast-enhanced MRI (DCE-MRI), positron emission tomography (PET) scan, and Integrated 18F-FDG PET/CT can be used during the diagnostic process of melanoma. DCE-MRI has the potential to be an in vivo imaging technique that can predict and isolate the patient group prone to metastatic disease. Integrated 18F-FDG PET/CT is useful in disease staging, therapy assessment, and determining prognosis. Positron emission tomography (PET) scan can help in diagnosing metastatic lesions.

Dynamic contrast-enhanced MRI

Dynamic contrast-enhanced MRI

  • Dynamic contrast-enhanced MRI can reveal different contrast enhancement patterns in relation to microvasculature and the expression of angiogenetic factor such as vascular endothelial growth factor.[1]
  • It can differentiate the tumor characterization between metastatic and non-metastatic melanoma by the Ktrans value.[2][1]
  • DCE-MRI has the potential to be an in vivo imaging technique that can predict and isolate the patient group prone to metastatic disease.[2]
Positron Emission Tomography (PET) Scan

Positron Emission Tomography (PET) Scan

  • Chest PET scan may be considered for diagnosis of metastatic lesions in the following conditions:[3]
  • For patients who have been diagnosed with stage IA-IV melanoma
  • For secondary prevention of melanoma among patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years)
Integrated 18F-FDG PET/CT

Integrated 18F-FDG PET/CT

  • Integrated 18F-FDG PET/CT is useful in disease staging, therapy assessment, and determining prognosis.[4]
References

References

  1. ↑ 1.0 1.1 Ovrebø KM, Ellingsen C, Galappathi K, Rofstad EK (May 2012). “Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts”. Int. J. Radiat. Oncol. Biol. Phys. 83 (1): e121–7. doi:10.1016/j.ijrobp.2011.12.019. PMID 22381901.
  2. ↑ 2.0 2.1 Wei W, Jia G, von Tengg-Kobligk H, Heverhagen JT, Abdel-Rahman M, Wei L, Christoforidis JB, Davidorf F, Knopp MV (2017). “Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential”. J Comput Assist Tomogr. 41 (5): 823–827. doi:10.1097/RCT.0000000000000598. PMID 28448404.
  3. ↑ Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). “Melanoma, version 2.2013: featured updates to the NCCN guidelines”. J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.
  4. ↑ Perng P, Marcus C, Subramaniam RM (August 2015). “(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis”. AJR Am J Roentgenol. 205 (2): 259–70. doi:10.2214/AJR.14.13575. PMID 26204273.


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.Sabawoon Mirwais, M.B.B.S, M.D.[2]